Q32 Bio (QTTB) shares took a hit Wednesday after the biotech company priced a public offering that's expected to bring in about $200 million. The stock was down 7.42% to $18.25 at the time of publication.
The offering consists of 6,027,399 common shares at $18.25 each and pre-funded warrants to purchase 4,931,506 shares at $18.2499 per warrant. Those warrants have an exercise price of just $0.0001 per share, meaning they're essentially already in the money. Underwriters also get a 30-day option to buy up to 1,643,835 additional shares at the offering price, minus discounts and commissions.
The deal is expected to close on or about July 16, 2026, assuming all the usual conditions are met. The estimated $200 million figure doesn't include any potential exercise of the underwriters' option or the pre-funded warrants.
What the Money Is For
Q32 Bio plans to use the net proceeds for working capital, research, clinical development, and commercialization activities — with a particular focus on future trials of bempikibart. That's the company's fully human anti-IL-7Rα antibody, which is currently being evaluated in an ongoing Phase 2 program for alopecia areata, an autoimmune condition that causes patchy hair loss.
Earnings and Analyst Views
Q32 Bio is expected to report earnings on August 5, 2026. Analysts are forecasting a loss of 56 cents per share, narrowing from a loss of 78 cents a year earlier. Revenue is projected at $600,000, compared with zero in the prior-year period.
Despite the stock's drop, Wall Street remains optimistic. The stock carries a Strong Buy consensus rating and an average price target of $33.25. Wells Fargo upgraded the stock to Overweight with a $66 price target on July 13. Oppenheimer maintained an Outperform rating and raised its target to $40 the same day. Mizuho initiated coverage with an Outperform rating and a $14 target back on May 22.
Valuation and Momentum
Q32 Bio has a Value score of 62.53 and a Momentum score of 99.84, according to market data. That suggests the stock offers moderate relative value but has shown exceptionally strong price momentum — though the offering could create some near-term pressure as investors digest the potential dilution.
